Immunobiologic consequences of assist devices

Cardiology Clinics

Volumn 21, Issue 1, 2003, Pages 119-133

  Itescu, Silviu ^a,b   Schuster, Michael ^a   Burke, Elizabeth ^a   Ankersmit, Jan ^a   Kocher, Alfred ^a   Deng, Mario ^a   John, Ranjit ^a   Lietz, Katherine ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOKINE; HLA DR3 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; T LYMPHOCYTE RECEPTOR;

B LYMPHOCYTE ACTIVATION; BIOPROSTHESIS; CYTOKINE PRODUCTION; FOREIGN BODY REACTION; HEART ASSIST DEVICE; HEART FAILURE; HEMODIALYSIS; HUMAN; IMMUNOBIOLOGY; IMMUNOMODULATION; IMMUNOREACTIVITY; MACROPHAGE; MONOCYTE; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION;

EID: 0037910377     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8651(02)00135-2     Document Type: Review

References (126)

1. Hognes JR. In the artificial heart: prototypes, policies and patients. Washington, DC: National Academy Press; 1991. p. 1-312.
2. Annual Report of the US Scientific Registry for Organ Transplantation and the Organ Procurement and Transplantation Network - 1990. Washington, DC: US Department of Health and Human Services;1990.
3. Frazier OH, Rose EA, Macmanus Q, et al. Multicenter clinical evaluation of the Heartmate 1000 IP left ventricular assist device. Ann Thorac Surg 1992;53:1080-90.
4. McCarthy PM, Portner PM, Tobler HG, et al. Clinical experience with the Novacor ventricular assist system. Bridge to transplantation and the transition to permanent application. J Thorac Cardiovasc Surg 1991;102:578-87.
5. Oz MC, Argenziano M, Catanese KA, et al. Bridge experience with long-term implantable left ventricular assist devices. Are they an alternative to transplantation? Circulation 1997;95:1844-52.
6. Merrit K, Brown SA. Tissue reaction and metal sensitivity: An animal study. Acta Orthop Scand 1980;51:403-11.
7. Glassman AH, Engh CA, Suthers KE. The year follow-up of total hip artheroplasty using extensively porous coated femoral components. Orthop Trans 1993;16:702.
8. Kaufman RI, Tong I, Beardmore TD. Prosthetic synovitis: clinical and histologic characteristics. J Rheumatol 1985;12(6):1066-74.
9. Maguire Jr JK, Coscia MF, Lynch MH. Foreign body reaction to polymeric debris following total hip artheroplasty. Clin Orthop 1987;218:213-223.
10. Kimber I, Bentley A, Hilton J. Contact sensitization of mice to nickel sulfate and potassium dichromate. Contact Dermatitis 1990;23:325-30.
11. Coleman RF, Herrington J, Scales JT. Concentration of wear products in hair, blood, after total hip replacement. BMJ 1973;1:527-9.
12. Merritt K, Brown SA. Effects of metal particles and ions on the biological system. Techn Orthop 1993;8:228-36.
13. Hakim RM. Clinical implications of hemodialysis membrane biocompatibility. Kidney Int 1993;44:484-94.
14. Radovich JM. Composition of polymer membranes for therapies of end-stage renal disease. Contrib Nephrol 1995;113:11-24.
15. Parnes EI, Shapiro WB. Anaphylactoid reactions in hemodialysis patients treated with AN69 dialyzers. Kidney Int 1991;40:1148-52.
16. Lo SK, Detmers PA, Levin SM, Wright SD. Transient adhesion of neutrophils to endothelium. J Exp Med 1989;169:1779-93.
17. Whele B, Bergstrom J, Kishimoto T, Lantz B, Levin N, Klinkmann H. β2-microglobulin and granulocyte elastase. Nephrol Dial Transplant 1993;8(Suppl 2):20-4.
18. Brubacker L, Nolph K. Mechanisms of recovery from neutropenia induced by hemodialysis. Blood 1971;38:623-31.
19. Grooteman MPC, Nube MJ, Daha MR, von Limbeek J, van Deuren M, Bet P, et al. Cytokine profiles during clinical high-flux dialysis: no evidence for cytokine generation by circulating monocytes. J Am Soc Nephrol 1997;8:1745-54.
20. Tielemans CL, Delville JPC, Husson CP, Madhoun P, Lambrechts AM, Goldman M, et al. Adhesion molecules and leucocyte commen antigen on monocytes and granulocytes during hemodialysis. Clin Nephrol 1993;39:158-63.
21. Thylen P, Lundahl J, Fernivik E, Hed J, Svenson SB, Jacobson SH. Mobilization of an intracellular glycoprotein (Mac-1) on monocytes and granulocytes during hemodialysis. Am J Nephrol 1992;12:393-400.
22. Schiller B, Ziegler-Heitbrock HWL, Meyer N, Schmidt B, Blumenstein M. Monocyte phenotype and interleukine-1 production in patients undergoing haemodialysis. Nephron 1991;59:573-9.
23. Ueki Y, Nagata M, Miyake S, Tominaga Y. Lymphocyte subsets in hemodialysis patients treated with recombinant erythropoietin. J Clin Immunol 1993;4:279-87.
24. Descamps-Latscha B, Herbelin A. Long-term dialysis and cellular immunity: a critical survey. Kidney Int 1993;43(Supp 41):S135-42.
25. Paczek L, Schaefer RM, Heidland A. Dialysis membranes decrease immunoglobulin and interleukin-6 production by peripheral blood mononuclear cells in vitro. Nephrol Dial Transplant 1991;6(Suppl 3):41-4.
26. Himmelfarb J, Hakim RM. Biocompatibility and risk of infection in haemodialysis patients. Nephrol Dial Transplant 1994;9(Suppl 2):138-44.
27. Mailloux LU, Belluci AG, Wilkes BM. Mortality in dialysis patients: analysis of the causes of death. Am J Kidney Dis 1991;3:326-35.
28. Didisheim P. Current concepts of thrombosis and infection in artificial organs. ASAIO J 1994;40(2):230-7.
29. Wagner WR, Johnson PC, Kormos RL, Griffith BP. Evaluation of bioprosthetic valve-associated thrombus in ventricular assist device patients. Circulation 1993;88(5Pt1):2023-9.
30. Rose EA, Levin HR, Oz MC, et al. Artificial circulatory support with textured interior surfaces. A counterintuitive approach to minimizing thromboembolism. Circulation 1994;50(5Pt2):1187-91.
31. Menconi MJ, Owen T, Dasse KA, Stein G, Lian JB. Molecular approaches to the characterization of cell and blood/biomaterial interactions. J Card Surg 1992;7(2):177-87.
32. Dasse KA, Chipman SD, Sherman CN, Levine AH, Frazier OH. Clinical experience with textured blood contacting surfaces in ventricular assist devices. ASAIO Trans 1987;33(3):418-25.
33. Spanier TB, Oz MC, Rose EA, et al. Activation of NF-KB is central to the proinflamatory/procoagulant response in textured surface left ventricular assist device recipients and may be influenced by anti-inflammatory intervention with aspirin. J Lung Heart Transpl 1997;17(1):80.
34. Spanier T, Oz M, Levin H, et al. Activation of coagulation and fibrinolytic pathways in patients with left ventricular assist devices. J Thorac Cardiovasc Surg 1996;112(4):1090-7.
35. Spanier TB, Rose S, Schmidt AM, Itescu S. Interactions between dentritic cells and T cells on the surface of left ventricular assist devices leads to a TH2 pattern of cytokine production and B cell hyperreactivity in vivo. Circulation 1996;94(Suppl 8):1704.
36. Weiss RA. How does HIV cause AIDS. Science 1993;260:1273-9.
37. Pantaleo G, Graziosi C, Demarest JF, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993;362(6418):355-8.
38. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271(5255):1582-6.
39. Safrit JT, Koup RA. The immunology of primary HIV infection: which immune responses control HIV replication. Curr Opin Immunol 1995;7(4):456-61.
40. Ameisen JC, Capron A. Cell dysfunction and depletion in AIDS: the programmed cell death hypothesis. Immunol Today 1991;12(4):102-5.
41. Groux H, Torpier G, Monte D, Mouton Y, Capron A, Ameisen JC. Activation-induced death by apoptosis in CD4+ T cells from human immunodeficiency virus infected asymptomatic individuals. J Exp Med 1992;175(2):331-40.
42. Katsikis PD, Wunderlich ES, Smith CA, Herzenberg LA, Herzenberg LA. Fas antigen stimulation induces marked apoptosis of T lymphocytes in human immunodeficiency virus-infected individuals. J Exp Med 1995;181(6):2029-36.
43. Orlikowski TWang ZQ, Dudhane A, Horowitz H, Riethmuller G, Hoffmann MK. Cytotoxic monocytes in the blood of HIV type 1-infected subjects destroy targeted T cells in a CD95-dependent fashion. AIDS Res Hum Retroviruses 1997;13:953-60.
44. Cameron PU, Pope M, Gezelter S, Steinman RM. Infection and apoptotic cell death of CD4+ T cells during an immune response to HIV-1-pulsed dendritic cells. AIDS Res Hum Retroviruses 1994;10(1):61-71.
45. Finkel TH, Monks C, Casella C, et al. Apoptosis and HIV disease. Nat Med 1995;1:386-7.
46. Ju ST, Panka DJ, Cui H, et al. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 1995;373:444-8.
47. Ledru E, Lecoeur H, Garcia S, Debord T, Gougeon ML. Differential susceptibility to activation-induced apoptosis among peripheral Th1 subsets: correlation with Bcl-2 expression and consequences for AIDS pathogenesis. J Immunol 1998;160(7):3194-206.
48. Brunner T, Mogil RJ, LaFace D, Yoo NJ, Mahboubl A, Echeverri F, et al. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T cell hybridomas. Nature 1995;373:441-4.
49. Dhein J, Walczak H, Baumler C, Debatin KM, Krammer PH. Autocrine T-cell suicide mediated by APO-1 (Fas/CD95). Nature 1995;373:438-41.
50. Ju ST, Panka DJ, Cui H, Ettinger R, E-Khatbl M, Sherr DH, et al. Fas(CD95)/Fas ligand interactions required for programmed cell death after T-cell activation. Nature 1995;373:444-8.
51. Lenardo MJ. Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis. Nature 1991;353:858-61.
52. Casiano CA, Martin SJ, Green DR, Tan EM. Selective cleavage of nuclear autoantigens during CD95 (Fa/APO-1)-mediated T cell apoptosis. J Exp Med 1996;184:765-78.
53. Casciola-Rosen L, Rosen A, Petri M, Schlissel M. Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: implications for coagulation events and antigenic spread in systemic lupus erythematosus. Proc Natl Acad Sci USA 1996;93:1624-9.
54. Bach JF. Immunology: new clues to systemic lupus. Lancet 1997;350(Suppl 3):SIII11.
55. Funauchi M, Ikoma S, Enomoto H, Horiuchi A. Decreased Th1-like and increased Th2-like cells in systemic lupus erythematosus. Scand J Rheumatol 1998;27:219-24.
56. Horwitz DA, Gray JD, Behrendsen SC, Kubin M, Rengaraju M, Ohtsuka K, et al. Decreased production of interleukin 12 and other Th1-type cytokines in patients with recent-onset systemic lupus erythematosus. Arthritis Rheum 1998;41:838-44.
57. Alcocer-Verela J, Alarcon-Segovia D. Decreased production of and response to IL-2 by cultured lymphocytes from patients with systemic lupus erythematosus. J Clin Invest 1982;69:1388-92.
58. Huang YP, Miescher PA, Zubler RH. The interleukin 2 secretion defect in vitro in patients with systemic lupus erythematosus is reversible in rested cultured T cells. J Immunol 1986;137:3515-20.
59. Klinman DM, Shirai A, Ishigatsubo Y, et al. Quantitation of IgM- and IgG-secreting B cells in the peripheral blood of patients with SLE. Arthritis Rheum 1991;34:11-5.
60. Bernard C, Exquis B, Reber A, et al. Determination of anticardiolipin and other antibodies in HIV-1 infected patients. J Acquir Immune Defic Syndr 1990;3:536-9.
61. Sollinger AM, Hess EV. Induction of autoanti-bodies by HIV infection and their significance. Rheum Dis Clin North Am 1991;17:157-76.
62. Casiano CA, Martin SJ, Green DR, Tan EM. Selective cleavage of nuclear autoantigens during CD95 (Fa/APO-1)-mediated T cell apoptosis. J Exp Med 1996;184:765-78.
63. Ameisen JC, Capron A. Cell dysfunction and depletion in AIDS: the programmed cell death hypothesis. Immunol Today 1991;12(4):102-5.
64. Groux H, Torpier G, Monte D, Mouton Y, Capron A, Ameisen JC. Activation-induced death by apoptosis in CD4+ T cells from human immunodeficiency virus infected asymptomatic individuals. J Exp Med 1992;175(2):331-40.
65. Mysler E, Bini P, Drappa J, Ramos P, Friedman SM, Krammer PH, et al. The APO-1/Fas protein in human systemic lupus erythematosus. J Clin Invest 1994;93:1029-34.
66. Perniok A, Wedekind F, Herrmann M, Specker C, Schneider M. High levels of circulating early apoptotic peripheral blood mononuclear cells in systemic lupus erythematosus. Lupus 1998;7:113-8.
67. Cameron PU, Pope M, Gezelter S, Steinman RM. Infection and apoptotic cell death of CD4+ T cells during an immune response to HIV-1-pulsed dendritic cells. AIDS Res Hum Retroviruses 1994;10(1):61-71.
68. Finkel TH, Monks C, Casella C, et al. Apoptosis and HIV disease. Nat Med 1995;1:386-7.
69. Funauchi M, Ikoma S, Enomoto H, Horiuchi A. Decreased Th1-like and increased Th2-like cells in systemic lupus erythematosus. Scand J Rheumatol 1998;27:219-24.
70. Horwitz DA, Gray JD, Behrendsen SC, Kubin M, Rengaraju M, Ohtsuka K, et al. Decreased production of interleukin 12 and other Th1-type cytokines in patients with recent-onset systemic lupus erythematosus. Arthritis Rheum 1998;41:838-44.
71. Clerici M, Shearer GM. The Th1-Th2 hypothesis of HIV infection: new insights. Immunol Today 1994;15:575-81.
72. Ledru E, Lecoeur H, Garcia S, Debord T, Gougeon ML. Differential susceptibility to activation-induced apoptosis among peripheral Th1 subsets: correlation with Bcl-2 expression and consequences for AIDS pathogenesis. J Immunol 1998;160:3194-206.
73. Brunner T, Mogil RJ, LaFace D, Yoo NJ, Mahboubl A, Echeverri F, et al. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T cell hybridomas. Nature 1995;373:441-4.
74. Dhein J, Walczak H, Baumler C, Debatin KM, Krammer PH. Autocrine T-cell suicide mediated by APO-1 (Fas/CD95). Nature 1995;373:438-41.
75. Ju ST, Panka DJ, Cui H, Ettinger R, E-Khatbl M, Sherr DH, et al. Fas(CD95)/Fas ligand interactions required for programmed cell death after T-cell activation. Nature 1995;373:444-8.
76. Boldin MP, Varfolomeev EE, Pancer Z, Mett IL, Camonis JH, Wallach D. A novel protein that interacts with the death domain of Fas/APO-1 contains a sequence motif related to the death domain. J Biol Chem 1995;270:7795-8.
77. Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995;81:505-12.
78. Boldin MP, Goncharov TM, Golstev YV, Wallach D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1 and TNF receptor-induced cell death. Cell 1996;85:803-15.
79. Muzio M, Chinnaiyan AM, Kischel FC, O'Rourke K, Shevchenko A, Ni J, et al. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 1996;85:817-27.
80. Hu S, Vicenz C, Ni J, Genz R, Dixit VM. I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1 and CD95-induced apoptosis. J Biol Chem 1997;272(28):17255-7.
81. Irmler M, Thorne M, Hahne M, Schneider P, Hofman K, Steiner V, et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997;388:190-5.
82. Refaeli Y, Van Parijs L, London CA, Tschopp J, Abbas AK. Biochemical mechanisms of IL-2 regulated Fas-mediated T cell apoptosis. Immunity 1998;8:615-23.
83. Goldstein D, El-Amir NG, Ashton RC, et al. Fungal infections in left ventricular assist device recipients - incidence, prophylaxis, and treatment. ASAIO 1995;41:873-5.
84. Holmann WL, Murrah CP, Ferguson ER, Bourge RC, McGiffin DC, Kirklin JK. Infections during extended circulatory support: University of Alabama at Birmingham experience 1989 to 1994. Ann Thorac Surg 1996;61:366-71.
85. McCarthy PM, Schmitt SK, Vargo RL, Gordon S, Keys TF, Hobbs RE. Implantable LVAD infections: implications for permanent use of the device. Ann Thorac Surg 1996;61:359-65.
86. Aussel C, Pelassy C, Breittmayer JP. CD95 (Fas/APO-1) induces an increased phosphatidyl-serine synthesis that precedes its externalization during programmed cell death. FEBS Lett 1998;431:195-9.
87. Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, Henson PM. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol 1992;148:2207-18.
88. Mevorach D, Zhou JL, Song X, Elkon KB. Systemic exposure to irradiated apoptotic cells induces autoantibody production. J Exp Med 1998;188:387-92.
89. Arnett FC, Reveille JD. Genetics of systemic lupus erythematosus. Rheum Dis Clin North Am 1992;18:865-92.
90. Davies EJ, Hillarby MC, Cooper RG, Hay EM, Green JR, Shah S, et al. HLA-DQ, DR and complement C4 variants in systemic lupus erythematosus. Br J Rheumatol 1993;32:870-5.
91. Kemp ME, Atkinson JP, Skanes VM, Levine RP, Chaplin DD. Deletion of C4A genes in patients with systemic lupus erythematosus. Arthritis Rheum 1987;30:1015-22.
92. Schur PH, Marcus-Bagley D, Awdeh ZL, Yunis EJ, Alper CA. The effect of ethnicity on major histocompatibility complex complement allotypes and extended haplotypes in patients with systemic lupus erythematosus. Arthritis Rheum 1990;33:985-92.
93. Jacob CO, Fronek Z, Lewis GD, Koo M, Hansen A, McDevitt HO. Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor alpha: relevance to genetic predisposition to systemic lupus erythematosus. Proc Natl Acad Sci USA 1990;87:1233-7.
94. Wilson AG, de Vries N, Pociot F, di Giovine FS, van der Putte LB, Duff GW. An allelic polymorphism within the tumor necrosis factor-alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J Exp Med 1993;177:557-60.
95. Wilson AG, Gordon C, di Giovane FS, de Vries N, van de Putte LB, Emery P, et al. A genetic association between systemic lupus erythematosus and tumor necrosis factor alpha. Eur J Immunol 1994;24:191-5.
96. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 1997;94:3195-9.
97. Bouma G, Crusius JB, Oudkerk Pool M, Kolkman JJ, von Blomberg BM, Kostense PJ, et al. Secretion of tumor necrosis factor alpha and lymphotoxin in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease. Scand J Immunol 1996;43:456-63.
98. Louis E, Franchimont D, Piron A, Gevaert Y, Schaaf-Lafontaine N, Roland S, et al. TNF gene polymorphism influences TNF-alpha production in LPS-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol 1998;113:401-6.
99. Devitt A, Moffatt OD, Raykundalia C, Capra JD, Simmons DL, Gregory CD. Human CD14 mediates recognition and phagocytosis of apoptotic cells. Nature 1998;392:505-9.
100. Chinnaiyan AM, Tepper CG, Seldin MF, O'Rourke K, Kischkel FC, Hellbardt S, et al. FADD/MORTI is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis. J Biol Chem 1996;271:4961-5.
101. Brunner T, Yoo NJ, LaFace D, Ware CF, Green DR. Activation-induced cell death in murine T cell hybridomas. Differential regulation of Fas (CD95) versus Fas ligand expression by Cyclosporin A and FK 506. Int Immunol 1996;8(7):11017-26.
102. Smith JD, Danskine AJ, Laylor RM, Rose ML, Yacoub MH. The effect of panel reactive antibodies and the donor specific crossmatch on graft survival after heartand heart-lung transplantation. Transpl Immunol 1993;1(1):60-5.
103. Joysey VC. Tissue typing, heart and heart-lung transplantation. Br J Biomed Sci 1993;50:272-6.
104. Ratkovec RM, Hammond EH, O'Connell JB, et al. Outcome of cardiac transplant recipients with a positive donor-specific crossmatch - preliminary results with plasmapharesis. Transplantation 1992;54(4):651-5.
105. John R, Lietz K, Burke E, Ankersmit J, Mancini D, Suciu-Foca N, et al. Intravenous immunoglobulin reduces anti-HLA alloreactivity and shortens waiting time to cardiac transplantation in highly sensitized left ventricular assist device recipients. Circulation 1999;100:II229-35.
106. Itescu S, Tung T, Burke E, Weinberg A, Oz M, Suciu-Foca N, et al. Preformed IgG antibodies against major histocompatibility class II antigens are major risk factors for high-grade cellular rejection in recipients of heart transplantation. Circulation 1998;98:786-93.
107. Liu Z, Colovai AI, Tugulea S, Reed EF, Fisher PE, Mancini D, et al. Indirect recognition of donor HLA-DR peptides in organ allograft rejection. J Clin Invest 1996;98:1150-7.
108. Tugulea S, Ciubotariu R, Colovai AI, Liu Z, Itescu S, Schulman L, et al. New strategies for early diagnosis of heart allograft rejection. Transplantation 1997;64:842-7.
109. Ciubotariu R, Liu Z, Itescu S, Colovai AI, Ho E, Ravalli S, et al. Persistent allopeptide reactivity and epitope spreading in chronic rejection of organ allografts. J Clin Invest 1997; In press.
110. Vanderlugt CJ, Miller SD. Epitope spreading. Curr Opin Immunol 1996;8:831-6.
111. Mamula MJ, Janeway Jr CA. Do B cells drive the diversification of immune responses? Immunol Today 1993;14:151-4.
112. Reed EF, Hong B, Ho E, Harris PE, Weinberger J, Suciu-Foca N. Monitoring of soluble HLA alloantigens and anti-HLA antibodies identifies heart allograft recipients at risk of transplant associated coronary artery disease. Transplantation 1996;61:556-72.
113. Glotz D, Haymann J, Sansonetti N, et al. Supression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (IVIg). Transplantation 1993;56:335-7.
114. Tyan DB, Li VA, Czer L, et al. Intravenous immunoglobulin suppresion of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation 1994;56:553-62.
115. Peraldi M, Akposso K, Havman J, et al. Long-term benefit of intravenous immunoglobulins in cadaveric kidney retransplantation. Transplantation 1996;62:1670-3.
116. McIntyre JA, Higgins N, Britton R, et al. Utilization of intravenous immunoglobulin to ameliorate alloantibodies in a highly sensitized patient with a cardiac assist device awaiting cardiac transplantation. Transplantation 1996;62:691-3.
117. De Marco T, Damon LE, Colombe B, et al. Successful immunomodulation with intravenous gamma globulin and cyclophosphamide in an alloimmunized heart transplant recipient. J Heart Lung Transplant 1997;16:360-5.
118. Dwyer JM. Manipulating the immune system with immune globulin. N Engl J Med 1992;326:107-16.
119. Dietrich G, Algiman M, Sultan Y, Nydegger UE, Kazatchkine MD. Origin of anti-idiotypic activity against anti-factor VIII autoantibodies in pools of normal human immunoglobulin G (IVIg). Blood 1992;79:2946-51.
120. Rossi F, Kazatchkine MD. Antiidiotypes against autoantibodies in pooled normal human polyspecific Ig. J Immunol 1989;143:4104-9.
121. Hurez V, Kaveri SV, Mouhoub A, et al. Anti-CD4 activity of normal human immunoglobulins for therapeutic use (IVIg). Ther Immunol 1993;1:269-78.
122. Vassilev T, Gelin C, Kaveri SV, et al. Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (IVIg). Clin Exp Immunol 1993;92:369-72.
123. Blasczyk R, Westhoff U, Grossewilde H. Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations. Lancet 1993;341:789-90.
124. Lam L, Whitsett CF, McNicholl JM, Hodge TW, Hooper J. Immunologically active proteins in intravenous immunoglobulin. Lancet 1993;342:678.
125. Itescu S, Burke E, Lietz K, et al. Intravenous pulse administration of cyclophosphamide is an effective and safe treatment for sensitized cardiac allograft recipients. Circulation 2002;105:1214-9.
126. Lin JS, Wei LJ. Linear regression analysis based on Buckley-James estimating equation. Biometrics 1992;48(3):679-81.